Proteins and Peptides

27 Jan 2018 Advanced Accelerator Applications Receives FDA Approval for Lutathera® for Treatment of Gastroenteropancreatic Neuroendocrine Tumors
25 Jan 2018 Synergy Pharmaceuticals Announces FDA Approval of TRULANCE® (Plecanatide) for the Treatment of Irritable Bowel Syndrome with Constipation (IBS-C) in Adults
25 Jan 2018 Generon Successfully Concludes First Phase III Clinical Trial of F-627 for Chemotherapy-Induced Neutropenia
24 Jan 2018 Biomarck Announces the Start of a Phase 2 Clinical Trial of BIO-11006 for Non-Small Cell Lung Cancer (NSCLC)
23 Jan 2018 FDA accepts investigational new drug application and grants Fast Track status for SOBI003 for the treatment of MPS IIIA
23 Jan 2018 New clinical evidence support potential for glepaglutide as a once-weekly drug for short bowel syndrome (SBS)
22 Jan 2018 Baxter Announces U.S. FDA Approval of Ready-to-Use Cardiovascular Medication Bivalirudin
22 Jan 2018 Octapharma: Low inhibitor rate with octanate® in previously untreated patients (PUPs) with severe haemophilia A
20 Jan 2018 Zealand Pharma announces progress to Phase 3 with dasiglucagon for the treatment of congenital hyperinsulinism in first half 2018
18 Jan 2018 FDA Approves Addition Of Overall Survival Data To KYPROLIS® (carfilzomib) Label
15 Jan 2018 Shire granted EU marketing authorization for ADYNOVI® [Antihemophilic Factor (Recombinant), PEGylated] for adults and adolescents with Hemophilia A
11 Jan 2018 RadioMedix and AREVA Med announce initiation of Phase 1 clinical trial of AlphaMedix(TM), a Targeted Alpha Therapy for patients with neuroendocrine tumors
09 Jan 2018 Revance Announces Interim Phase 2a Results for RT002 in Treating Plantar Fasciitis
09 Jan 2018 WACKER Obtains FDA Approval to Manufacture the Drug Substance in Retavase®, a Thrombolysis Medication by Chiesi
09 Jan 2018 Ra Pharmaceuticals Initiates Dosing in Phase 1b Pharmacokinetic Study Evaluating RA101495 SC in Patients with Renal Impairment
08 Jan 2018 Molecular Partners reports promising initial safety and efficacy data from its ongoing phase 2 study of MP0250 in multiple myeloma
04 Jan 2018 Spitfire Pharma's SP-1373 outscored semaglutide and elafibranor in a biopsy-proven translational mouse model of non-alcoholic steatohepatitis (NASH)
04 Jan 2018 Enteris BioPharma Announces Positive Results from Phase 2a Clinical Trial of Ovarest® (oral leuprolide tablet) for Endometriosis
04 Jan 2018 Catalyst Biosciences Initiates Phase 2/3 Trial of Marzeptacog Alfa (activated) for Prophylaxis in Hemophilia A or B with Inhibitors
03 Jan 2018 Palatin Technologies, Inc. Announces FDA Clearance of Investigational New Drug (IND) Application for PL-8177 For Ulcerative Colitis
02 Jan 2018 Longevity Biotech Awarded $225K Phase I SBIR Contract From NHLBI/NIH to Develop 5A apoA-I Mimetic Peptide for Treatment of Severe Asthma
22 Dec 2017 Ra Pharmaceuticals Initiates Dosing in Phase 2 Clinical Trial Evaluating RA101495 SC in Generalized Myasthenia Gravis Patients
22 Dec 2017 BioLineRx Announces Initiation of Phase 3 GENESIS Trial in Stem-Cell Mobilization for Autologous Transplantation in Multiple Myeloma Patients
22 Dec 2017 Savara Submits Investigational New Drug Application to FDA for Expansion of Molgradex Impala Study Into U.S.
22 Dec 2017 La Jolla Pharmaceutical Company Announces FDA Approval of Giapreza™ (angiotensin II)

La Merie Biologics

FREE Weekly News Bulletin

Sign Up

2017 Sales ofAntibodies & Proteins

New Product Alert

For La Merie Publishing

Sign Up